• Explore /
  • Poster
  • / Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma.

Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma.

Abstract Poster

Authors

null

Rachael A Safyan

Columbia University Irving Medical Center, New York, NY

Rachael A Safyan , Gulam Abbas Manji , Shing Mirn Lee , Rebecca Silva , Susan Elaine Bates , Ruth Aroon White , Jacob K.R. Jamison , Adam Joel Bass , Gary K. Schwartz , Paul Eliezer Oberstein , Tamas Gonda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT03264404

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4158)

DOI

10.1200/JCO.2022.40.16_suppl.4158

Abstract #

4158

Poster Bd #

143

Abstract Disclosures

Similar Posters

First Author: Rachael A Safyan

First Author: Kim Anna Reiss

First Author: Rachel Frascati

Poster

2023 ASCO Annual Meeting

Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.

Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.

First Author: Nan Chen